

**EXHIBIT 3: Relevant Examples From U.S. Patent No. 6,316,029 for
 "Rapidly Disintegrating Oral Dosage Form" Showing Fast Dissolution of Nanoparticulate
 Active Agent Dosage Forms Comprising a Cellulosic Polymer**

Example	Drug	Surface Stabilizer(s)	Spray Dried or Granulated Intermediate (w/w)	Other Excipients (w/w)	Dissolution Time (in water)
Examples 1 and 2 of USPN 6,316,029	-COX-2 inhibitor type NSAID -mean particle size of 120 nm	hydroxypropyl cellulose SL (HPC-SL) and sodium lauryl sulfate (SLS)	37.3% (20% drug, 4% HPC-SL, 0.12% SLS, and lactose)	36.5% Fructose 12.15% sorbitol 8% croscarmellose sodium 5% citric acid 1% magnesium stearate	108-111 seconds
Example 12 of USPN 6,316,029 (Tablet A)	nano particulate naproxen	hydroxypropyl cellulose (HPC)	66.7% (28.5% drug, 5.7% HPC, and lactose)	30% lactose 0% mannitol 3% croscarmellose sodium 0.5% magnesium stearate	54 sec.
Example 12 of USPN 6,316,029 (Tablet B)	nano particulate naproxen	hydroxypropyl cellulose (HPC)	66.7% (28.5% drug, 5.7% HPC, and lactose)	0% lactose 30% mannitol 3% croscarmellose sodium 0.5% magnesium stearate	33 sec.
Example 13 of USPN 6,316,029	nifedipine D90<510 nm	hydroxypropyl cellulose (HPC) and sodium lauryl sulphate (SLS).	10.71% (10% nifedipine, 2% HPC, 0.1% SLS, and 10% mannitol)	12.59% mannitol 38.04% xylitol 18.39% citric acid 18.21% sodium bicarbonate 0.27% Aspartame® 0.89% PEG 4000	42-65 sec. (25 different tablets were tested)
Example 14 of USPN 6,316,029	glipizide D90<660 nm	hydroxypropyl cellulose (HPC)	5.33% (10% glipizide, 2% HPC, and mannitol)	0.90% sodium stearyl fumerate 13.4% mannitol 40.53% xylitol 19.60% citric acid 19.33% sodium bicarbonate 0.28% Aspartame® 0.93% PEG 4000 0.53% sodium stearyl fumerate	average of 43 sec.